Assessing the efficacy of clinical drugs targeting SARS-CoV-2 main protease
In 2021, the FDA approved nirmatrelvir (NTV) as the first oral antiviral drug targeting M pro, marketed under the brand name Paxlovid. Despite its initial ... The authors first compared the chemical ...